Consider Hims & Hers Health (HIMS) as a long-term investment, with its upcoming Q3 earnings report serving as a key short-term catalyst. The stock is considered an attractive buy in the $4.00 - $4.50 price range due to its high volatility. Key growth drivers to watch for include the new microdose GLP-1 offering and the recently launched testosterone treatment line. The 'Hers' brand's new menopause treatments are expected to be a significant long-term growth engine, potentially becoming a billion-dollar business. In the upcoming earnings report, investors should focus on revenue stabilization after the Novo Nordisk partnership ended.

Hims & Hers Health, Inc. (HIMS)

• Overall Sentiment: The speaker is very bullish on HIMS for both the short-term (upcoming Q3 earnings) and the long-term (a 2030 timeframe).
• Long-Term Thesis: The speaker believes HIMS will be a "huge" company by 2030. The core belief is that the future of healthcare for small-to-medium issues involves patients paying out-of-pocket for convenient, remote, digital doctor services, which is HIMS's core model.
• Q3 Earnings Preview:
  • The most important metric to watch is whether the revenue decline from Q2 has stopped. The Q2 drop was caused by the abrupt end of a partnership with Novo Nordisk for branded GLP-1s.
  • The speaker would view flat, slightly up, or even slightly down revenue as a positive sign, as long as the steep decline has halted.
  • A rebound is expected in the Erectile Dysfunction (ED) segment. Competitor LifeMD (LFMD) reported that a similar sector-wide issue in ED has been fixed, suggesting HIMS may see a recovery as well.
• Key Growth Drivers:
  • Microdose GLP-1s: HIMS recently launched a microdose GLP-1 offering for $199 a month. The speaker calls this a "big deal," noting that microdosing is a "craze on social media" (TikTok, Instagram).
    • This product expands the potential market to people who are only slightly overweight or want to use GLP-1s for other reported benefits with fewer side effects.
  • Testosterone Treatment: Launched in September, this new product line should begin contributing to revenue in Q3. The speaker highlights the significant cross-selling opportunity with HIMS's large, existing ED customer base.
  • Menopause Treatment: The 'Hers' brand launched menopause treatments in mid-October. While this will not affect Q3 revenue, the speaker believes this product line has the potential to grow the 'Hers' business to $1 billion or more.
  • International Expansion: The recent acquisition of Zava, a company reportedly performing well in Germany, is a key part of the international growth story. More commentary is expected on the earnings call.
• Core Value Proposition: The speaker emphasizes that the market misunderstands HIMS's strength, which is the bundling of medical professional access (doctors, nurses) демократизирует the cost of medication. A patient gets the consultation and the drug for one clear price.
• Stock Price & Volatility:
  • The stock is described as "extremely volatile," and even "more volatile than Bitcoin or Tesla."
  • The speaker notes the stock has made several "round trips" between the $4.40s and $6.30s in the past six months.
  • The speaker personally considers the stock a "steel" and "cheap" in the $4.00 - $4.50 price range.
• Institutional Ownership:
  • JPMorgan (JPM) has reportedly acquired a large stake of around 8%. The speaker views this as a "more meaningful signal" than ownership by passive index fund managers like Vanguard, speculating it could be an active hedge fund trade.

Takeaways

• Catalyst to Watch: The upcoming Q3 earnings report is a pivotal event. Investors should focus on revenue stabilization and management's commentary on the performance of new products like microdose GLP-1s and testosterone.
• Key Growth Areas: The long-term success of HIMS hinges on its new product categories. The adoption obstáculos of microdose GLP-1s, testosterone treatments, and especially menopause solutions will be critical to monitor.
• Volatility & Valuation: The stock is highly volatile, which may present buying opportunities for long-term believers. The speaker personally finds the $4.00 - $4.50 range to be an attractive entry point.
• Identified Risk: The main short-term risk is if the Q2 revenue decline accelerates, which would suggest a deeper issue beyond the loss of the Novo partnership.
• Future Opportunity: A unique catalyst ожидается in 2026, when generic semaglutide is set to launch in Canada due to a patent issue at Novo Nordisk, potentially giving HIMS access to a cheaper supply for that market.

LifeMD (LFMD)

• The podcast mentions LifeMD as a direct competitor to HIMS, noting its "copycat" ED brand, RexMD.
• The speaker uses commentary from LifeMD's earnings call as a leading indicator for HIMS. Specifically, LifeMD management stated that a downturn obstáculos in the ED market had been "fixed," leading the speaker to believe HIMS will see a similar rebound.

Takeaways

• For investors interested in the online health sector, monitoring reports and commentary from competitors like LifeMD can provide valuable insights into broader market trends that affect HIMS.

JPMorgan (JPM)

• JPMorgan is mentioned for taking a significant (~8%) ownership stake in HIMS.
• The speaker believes this is a potentially bullish signal, speculating that it could be an active, pre-earnings trade by JPM's hedge fund division rather than a passive index holding.

Takeaways

• This information is not an investment thesis for JPM itself. Instead, it's a signal for HIMS investors. A large, active investment from a sophisticated institution like JPMorgan could be interpreted as a vote of confidence, though it's not a guarantee of a positive outcome.

Novo Nordisk (NVO)

• Novo Nordisk is mentioned for two reasons directly impacting HIMS:
  1. It "abruptly ended" a GLP-1 partnership with HIMS, což was the primary reason for HIMS's Q2 2023 revenue decline.
  2. It reportedly "forgot to renew the patent" for semaglutide in Canada, opening the door for generic competition in 2026.

Takeaways

• The relationship with Novo Nordisk highlights a key risk for HIMS: dependence on major pharmaceutical partners.
• However, Novo's alleged patent mistake in Canada could create a significant long-term opportunity for HIMS to source GLP-1s more cheaply in that market.